Progress of myeloid differentiation factor 88 L265P mutation in B-cell proliferative neoplasms

VernacularTitle: 髓样分化因子88 L265P突变在B细胞增殖性肿瘤中的研究进展
Author: Xiaoxiao HAN ¹ ; Yuexin CHENG ; Hao XU
Author Information

1. Department of Hematology, Yancheng City No.1 People's Hospital, the Fourth Affiliated Hospital of Nantong University, Yancheng Hospital Affiliated of Xuzhou Medical University, Yancheng 224006, China
Publication Type:Review
Keywords: Myeloid differentiation factor 88 L265P mutation; Lymphoplasmacytic lymphoma/Waldenstrom' s macroglobulinemia; Lymphoma, large B-cell, diffuse; Leukemia, lymphocytic, chronic, B-cell; Marginal zone lymphoma
From: Journal of Leukemia & Lymphoma 2018;27(8):501-505
CountryChina
Language:Chinese
Abstract: Myeloid differentiation factor 88 (MYD88) is a key linker in the Toll-like receptor (TLR) signaling pathway, which plays an important role in the progression of the tumour. Recent studies have shown that the activating mutation of MYD88 L265P has been identified in about of 90% lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia and about of 40% diffuse large B-cell lymphoma and other subtypes of B-cell proliferative neoplasms. Different types of B-cell proliferative neoplasms have their own histology, immunohistochemistry and clinical characteristics, thus, mutation rates of MYD88 L265P are different. This review discusses the latest progress of MYD88 L265P mutation in B-cell proliferative neoplasms.